Chemical Property of 6-(Dimethylamino)-4,4-diphenylheptan-3-one;hydron;chloride
Chemical Property:
- Appearance/Colour:White solid
- Vapor Pressure:1.59E-09mmHg at 25°C
- Melting Point:232-2340C
- Refractive Index:1.5790 (estimate)
- Boiling Point:423.7 °C at 760 mmHg
- Flash Point:126.5 °C
- PSA：17.07000
- Density:1.0103 (rough estimate)
- LogP:1.25300
- Storage Temp.:2-8°C
- Solubility.:Soluble in water, freely soluble in ethanol (96 per cent)
- Water Solubility.:120 mg/mL
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:3
- Rotatable Bond Count:7
- Exact Mass:345.1859422
- Heavy Atom Count:24
- Complexity:346
- Purity/Quality:
-
Safty Information:
- Pictogram(s):
T, 
F
- Hazard Codes:T,F
- Statements:
25-39/23/24/25-23/24/25-11
- Safety Statements:
45-36/37-16
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:[H+].CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-]
-
Description
(±)-Methadone (hydrochloride) (Item No. ISO00145) is an analytical reference material categorized as an opioid. (±)-Methadone has analgesic activity. Formulations containing (±)-methadone have been used in the treatment of opioid addiction. (±)-Methadone is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.
-
Uses
Controlled substance (opiate). Methadone hydrochloride is used in treatment of opioid dependence.
-
Therapeutic Function
Narcotic analgesic
-
Clinical Use
Treatment of opioid drug addiction
Analgesic for moderate to severe pain
-
Drug interactions
Metabolised in the liver to the Potentially hazardous interactions with other drugs
Analgesics: possible opioid withdrawal with
buprenorphine and pentazocine.
Antibacterials: metabolism increased by rifampicin;
increased risk of ventricular arrhythmias with
delamanid and telithromycin.
Antidepressants: concentration possibly increased
by fluoxetine, fluvoxamine, paroxetine and sertraline;
possible CNS excitation or depression with MAOIs
and moclobemide - avoid; possibly increased
sedative effects with tricyclics; concentration possibly
reduced by St John's wort.
Antiepileptics: concentration reduced by
carbamazepine, phenobarbital and phenytoin.
Antifungals: concentration increased by fluconazole,
ketoconazole, voriconazole and possibly itraconazole
- may need to reduce methadone dose with
voriconazole, avoid with ketoconazole.
Antihistamines: increased sedative effects with
sedating antihistamines.
Antimalarials: increased risk of ventricular
arrhythmias with piperaquine with artenimol -
avoid.
Antipsychotics: enhanced hypotensive and sedative
effects; increased risk of ventricular arrhythmias with
antipsychotics that prolong the QT interval - avoid
with amisulpride.
Antivirals: methadone possibly increases
concentration of zidovudine; concentration
reduced by efavirenz, fosamprenavir and ritonavir;
concentration possibly reduced by abacavir,
nevirapine and rilpivirine; concentration possibly
affected by boceprevir; concentration of didanosine
possibly reduced; increased risk of ventricular
arrhythmias with saquinavir and telaprevir - avoid
with saquinavir and use with caution with telaprevir.
Atomoxetine: increased risk of ventricular
arrhythmias.
Cytotoxics: possible increased risk of ventricular
arrhythmias with bosutinib, ceritinib, panobinostat
and vandetanib.
Dopaminergics: avoid with selegiline.
Nalmefene: avoid concomitant use.
Sodium oxybate: enhanced effect of sodium oxybate
- avoid
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
